Accessibility Statement
1. Commitment
Sanofi is committed to providing digital solutions that are accessible to the widest possible audience, regardless of ability, disability, race, cultural background, gender, or technological requirements.
This accessibility statement applies to www.nuvaxovid.com.
2. Conformance status: Partial Compliance
The Web Content Accessibility Guidelines (WCAG) defines requirements for designers and developers to improve accessibility for people with disabilities. It defines three levels of conformance: Level A, Level AA, and Level AAA. This website is partially conformant with WCAG 2.2 Level AA, due to the limitations described below.
3. Known limitations
Despite our best efforts to ensure the accessibility of this website, there may be some limitations. Below is a description of known limitations and potential solutions. Please contact us if you observe an issue not listed below.
-
ARIA attributes: Certain elements with ARIA roles may have invalid or missing attributes
-
Programmatic roles and states: Some interactive components may not expose complete role, state, or value information to assistive technologies
-
Color contrast: Some text and link elements do not meet minimum color contrast requirements
-
Context-dependent links: Certain links may rely on surrounding context to be understood
-
Embedded content titles: Embedded frames or external content may not always include descriptive titles
4. Feedback and contact
Please contact us if you encounter accessibility barriers on this website. If you are unable to access any content or service, we will provide an accessible alternative or offer the content in another form.
5. Preparation of this accessibility statement
This statement was prepared on May 14, 2026.
To evaluate the current level of accessibility, the website was assessed using automated testing in Axe Monitor, based on WCAG 2.2 Level AA, with Google Chrome.
6. Formal complaints
If you are not satisfied with our response to you, you are entitled to escalate a complaint to the national authority.
To file an Americans with Disabilities (ADA) complaint, submit a report with the US Department of Justice, Civil Rights Division, online or by mail. Learn how to file a complaint on the Civil Rights Division website.
Important Safety Information
You or your child should not get NUVAXOVID if you had a severe allergic reaction to a previous dose of NUVAXOVID or to any of its ingredients.
There is a remote chance that the vaccine could cause a severe allergic reaction, which would usually occur within a few minutes to one hour after getting a dose. For this reason, the vaccination provider may ask you or your child to stay at the place where you or your child received the vaccine for monitoring after vaccination. Signs of a severe allergic reaction can include: difficulty breathing, swelling of the face and throat, a fast heartbeat, a bad rash all over the body and/or dizziness and weakness.
Myocarditis (inflammation of the heart muscle) and pericarditis (inflammation of the lining outside the heart) have occurred in some people who have received NUVAXOVID. The chance of having this occur is very low. You should seek medical attention right away if you or your child have any of the following symptoms after receiving the vaccine: chest pain; shortness of breath; feelings of having a fast-beating, fluttering, or pounding heart.
Other side effects reported in clinical trials and/or post-approval use of NUVAXOVID include: Injection site reactions (pain/tenderness, swelling, redness and itching), fatigue or generally feeling unwell, muscle pain, headache, joint pain, nausea, vomiting, fever, chills, allergic reactions such as hives and swelling of the face, swollen lymph nodes, paresthesia (unusual feeling in the skin such as tingling or a crawling feeling), and hypoesthesia (decreased feeling or sensitivity, especially in the skin).
Indication
NUVAXOVID is a vaccine to protect against COVID-19 for people who are:
- 65 years of age and older, or
- 12 years through 64 years of age at high risk for severe COVID-19
Vaccination with NUVAXOVID may not protect all people who receive the vaccine.
NUVAXOVID does not contain SARS-CoV-2, the virus that causes COVID-19. NUVAXOVID cannot give you or your child COVID-19.
Learn more about Sanofi's commitment to fighting counterfeit drugs.
Important Safety Information
You or your child should not get NUVAXOVID if you had a severe allergic reaction to a previous dose of NUVAXOVID or to any of its ingredients.
There is a remote chance that the vaccine could cause a severe allergic reaction, which would usually occur within a few minutes to one hour after getting a dose. For this reason, the vaccination provider may ask you or your child to stay at the place where you or your child received the vaccine for monitoring after vaccination. Signs of a severe allergic reaction can include: difficulty breathing, swelling of the face and throat, a fast heartbeat, a bad rash all over the body and/or dizziness and weakness.
Myocarditis (inflammation of the heart muscle) and pericarditis (inflammation of the lining outside the heart) have occurred in some people who have received NUVAXOVID. The chance of having this occur is very low. You should seek medical attention right away if you or your child have any of the following symptoms after receiving the vaccine: chest pain; shortness of breath; feelings of having a fast-beating, fluttering, or pounding heart.
Other side effects reported in clinical trials and/or post-approval use of NUVAXOVID include: Injection site reactions (pain/tenderness, swelling, redness and itching), fatigue or generally feeling unwell, muscle pain, headache, joint pain, nausea, vomiting, fever, chills, allergic reactions such as hives and swelling of the face, swollen lymph nodes, paresthesia (unusual feeling in the skin such as tingling or a crawling feeling), and hypoesthesia (decreased feeling or sensitivity, especially in the skin).
Indication
NUVAXOVID is a vaccine to protect against COVID-19 for people who are:
- 65 years of age and older, or
- 12 years through 64 years of age at high risk for severe COVID-19
Vaccination with NUVAXOVID may not protect all people who receive the vaccine.
NUVAXOVID does not contain SARS-CoV-2, the virus that causes COVID-19. NUVAXOVID cannot give you or your child COVID-19.
Learn more about Sanofi's commitment to fighting counterfeit drugs.
Important Safety Information
You or your child should not get NUVAXOVID if you had a severe allergic reaction to a previous dose of NUVAXOVID or to any of its ingredients.
There is a remote chance that the vaccine could cause a severe allergic reaction, which would usually occur within a few minutes to one hour after getting a dose. For this reason, the vaccination provider may ask you or your child to stay at the place where you or your child received the vaccine for monitoring after vaccination. Signs of a severe allergic reaction can include: difficulty breathing, swelling of the face and throat, a fast heartbeat, a bad rash all over the body and/or dizziness and weakness.
Myocarditis (inflammation of the heart muscle) and pericarditis (inflammation of the lining outside the heart) have occurred in some people who have received NUVAXOVID. The chance of having this occur is very low. You should seek medical attention right away if you or your child have any of the following symptoms after receiving the vaccine: chest pain; shortness of breath; feelings of having a fast-beating, fluttering, or pounding heart.
Other side effects reported in clinical trials and/or post-approval use of NUVAXOVID include: Injection site reactions (pain/tenderness, swelling, redness and itching), fatigue or generally feeling unwell, muscle pain, headache, joint pain, nausea, vomiting, fever, chills, allergic reactions such as hives and swelling of the face, swollen lymph nodes, paresthesia (unusual feeling in the skin such as tingling or a crawling feeling), and hypoesthesia (decreased feeling or sensitivity, especially in the skin).
Indication
NUVAXOVID is a vaccine to protect against COVID-19 for people who are:
- 65 years of age and older, or
- 12 years through 64 years of age at high risk for severe COVID-19
Vaccination with NUVAXOVID may not protect all people who receive the vaccine.
NUVAXOVID does not contain SARS-CoV-2, the virus that causes COVID-19. NUVAXOVID cannot give you or your child COVID-19.
Learn more about Sanofi's commitment to fighting counterfeit drugs.